Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
出版年份 2021 全文链接
标题
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
作者
关键词
-
出版物
AUTOIMMUNITY REVIEWS
Volume -, Issue -, Pages 102750
出版商
Elsevier BV
发表日期
2021-01-20
DOI
10.1016/j.autrev.2021.102750
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?
- (2020) Marcella Prete et al. AUTOIMMUNITY REVIEWS
- Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
- (2020) Vijayabhaskar Veeravalli et al. DRUG SAFETY
- SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment
- (2020) Marcella Prete et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
- (2020) Pavine L C Lefevre et al. Journal of Crohns & Colitis
- JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
- (2020) Azucena Salas et al. Nature Reviews Gastroenterology & Hepatology
- Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
- (2020) Moshe Talpaz et al. LEUKEMIA
- A review of upadacitinib in rheumatoid arthritis
- (2020) Yoshiya Tanaka Modern Rheumatology
- Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Randomized, Double‐blind, Active‐comparator, Multi‐center, Multi‐country Trial
- (2020) Ronald van Vollenhoven et al. Arthritis & Rheumatology
- Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
- (2020) Andrea Rubbert-Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
- (2019) Anniina T. Virtanen et al. BIODRUGS
- Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis
- (2019) Paolo Strati et al. ANNALS OF HEMATOLOGY
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
- (2019) Roy M Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial
- (2019) Roy Fleischmann et al. Arthritis & Rheumatology
- JAK inhibitors for the treatment of autoimmune and inflammatory diseases
- (2019) Yvan Jamilloux et al. AUTOIMMUNITY REVIEWS
- Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia
- (2019) Qing-Yun Wu et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
- (2019) Katie Bechman et al. PHARMACOLOGICAL RESEARCH
- Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial
- (2019) Asra Ahmed et al. Lancet Haematology
- FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease
- (2019) Donna Przepiorka et al. ONCOLOGIST
- In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors
- (2019) Yukihiro Kitanaga et al. RHEUMATOLOGY
- Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
- (2018) Ian C. Scott et al. DRUG SAFETY
- Nicorandil and theophylline can protect experimental rats against complete Freund's adjuvant-induced rheumatoid arthritis through modulation of JAK/STAT/RANKL signaling pathway
- (2018) Ahmed Gaafar Ahmed Gaafar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
- (2018) Eric Van Den Neste et al. HAEMATOLOGICA
- Germline JAK2 L611S mutation in a child with thrombocytosis
- (2018) Bernard Aral et al. HAEMATOLOGICA
- Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort
- (2018) Piero Ruscitti et al. JOURNAL OF RHEUMATOLOGY
- Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
- (2018) Mark C Genovese et al. LANCET
- Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
- (2018) Gerd R Burmester et al. LANCET
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia
- (2018) Michiko Nemoto et al. Scientific Reports
- A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
- (2018) Eric Van Den Neste et al. HAEMATOLOGICA
- Germline JAK2 L611S mutation in a child with thrombocytosis
- (2018) Bernard Aral et al. HAEMATOLOGICA
- The role of the JAK/STAT signal pathway in rheumatoid arthritis
- (2018) Charles J. Malemud Therapeutic Advances in Musculoskeletal Disease
- JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene
- (2018) Gigliola Di Matteo et al. Molecular Genetics & Genomic Medicine
- A comprehensive review on adult onset Still's disease
- (2018) Roberto Giacomelli et al. JOURNAL OF AUTOIMMUNITY
- The molecular details of cytokine signalling via the JAK/STAT pathway
- (2018) Rhiannon Morris et al. PROTEIN SCIENCE
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Association between hyperleptinemia and cardiovascular outcomes in patients with coronary artery disease
- (2018) Ming-Chun Chen et al. Therapeutics and Clinical Risk Management
- A Novel Homozygous JAK3 Mutation Leading to T-B+NK– SCID in Two Brazilian Patients
- (2018) Lucila A. Barreiros et al. Frontiers in Pediatrics
- “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
- (2018) Emira Bousoik et al. Frontiers in Oncology
- The Jakinibs in systemic lupus erythematosus: progress and prospects
- (2018) Chi Chiu Mok EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia
- (2018) Qing-Yun Wu et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation
- (2017) Laura Eder-Azanza et al. HAEMATOLOGICA
- Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry
- (2017) Ennio G. Favalli et al. International Journal of Rheumatic Diseases
- Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
- (2017) S Degryse et al. LEUKEMIA
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations
- (2017) Jing Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial
- (2017) Vibeke Strand et al. ARTHRITIS CARE & RESEARCH
- Critical functions for STAT5 tetramers in the maturation and survival of natural killer cells
- (2017) Jian-Xin Lin et al. Nature Communications
- A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH
- (2017) Teresa Sadras et al. Cancer Genetics
- Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications
- (2017) Shuyu D. Li et al. Genome Medicine
- p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation
- (2017) Laura Eder-Azanza et al. HAEMATOLOGICA
- Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis
- (2017) Joel M. Kremer et al. Arthritis & Rheumatology
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Cytokine Signaling in Tumor Progression
- (2017) Myungmi Lee et al. Immune Network
- Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
- (2016) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Vasculitides: Proposal for an integrated nomenclature
- (2016) Marcella Prete et al. AUTOIMMUNITY REVIEWS
- Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera
- (2016) L. Lanikova et al. BLOOD
- Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia
- (2016) K. Kapralova et al. BLOOD
- Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
- (2016) R. Das et al. BLOOD
- Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice
- (2016) Sophia Maschalidi et al. BLOOD
- Deep intronic mis-splicing mutation in JAK3 gene underlies T−B+NK− severe combined immunodeficiency phenotype
- (2016) Polina Stepensky et al. CLINICAL IMMUNOLOGY
- Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
- (2016) Mohamed-Eslam F. Mohamed et al. CLINICAL PHARMACOKINETICS
- The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus
- (2016) Aleš Goropevšek et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- The JAK/STAT pathway in obesity and diabetes
- (2016) Esteban N. Gurzov et al. FEBS Journal
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
- (2016) Rein M. G. J. Houben et al. PLOS MEDICINE
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
- (2015) J. D. Milosevic Feenstra et al. BLOOD
- JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
- (2015) L. Springuel et al. HAEMATOLOGICA
- Effects of the I682F mutation on JAK2's activity, structure and stability
- (2015) Feng Li et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
- (2015) Alexandra Y. Kreins et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development
- (2015) A M Roncero et al. LEUKEMIA
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- Differential Role of Leptin and Adiponectin in Cardiovascular System
- (2015) C. M. Ghantous et al. International Journal of Endocrinology
- Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
- (2015) Shuqun Yang et al. Oncotarget
- JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
- (2015) L. Springuel et al. HAEMATOLOGICA
- The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia
- (2014) D. Schinnerl et al. BLOOD
- JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model
- (2014) S. Degryse et al. BLOOD
- Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors
- (2014) C. Marty et al. BLOOD
- JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis
- (2014) Ugo Fiocco et al. IMMUNOLOGIC RESEARCH
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adipokines, Metabolic Syndrome and Rheumatic Diseases
- (2014) Vanessa Abella et al. Journal of Immunology Research
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Regulation of Janus kinases by SOCS proteins
- (2013) Nadia J. Kershaw et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
- (2013) Takaomi Sanda et al. Cancer Discovery
- JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis
- (2012) Clara Dees et al. ARTHRITIS AND RHEUMATISM
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
- (2012) Kathryn G. Roberts et al. CANCER CELL
- The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia
- (2012) H. J. Lee et al. CLINICAL CANCER RESEARCH
- Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity
- (2012) Jeffrey J. Babon et al. IMMUNITY
- Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia
- (2012) T Bains et al. LEUKEMIA
- Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained
- (2012) Thomas E. Witzig et al. LEUKEMIA & LYMPHOMA
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK/STAT signaling in hematological malignancies
- (2012) W Vainchenker et al. ONCOGENE
- Constitutive Phosphorylation of Interferon Receptor A-Associated Signaling Proteins in Systemic Lupus Erythematosus
- (2012) Gabriela Ramírez-Vélez et al. PLoS One
- Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection: up-regulation of inflammation-associated STAT1, IRF1, CXCL9, CXCL10, and CCL5
- (2012) S Yoshida et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor
- (2012) Maria A Argiriadi et al. BMC STRUCTURAL BIOLOGY
- SOCS, Inflammation, and Autoimmunity
- (2012) Akihiko Yoshimura et al. Frontiers in Immunology
- Switching rheumatoid arthritis treatments: An update
- (2011) Fabiola Atzeni et al. AUTOIMMUNITY REVIEWS
- JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma
- (2011) K. Van Roosbroeck et al. BLOOD
- FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
- (2011) N. E. Elliott et al. BLOOD
- Leptin in immuno-rheumatological diseases
- (2011) Marta Vadacca et al. Cellular & Molecular Immunology
- Differential biological activity of disease-associated JAK2 mutants
- (2011) Haiying Zou et al. FEBS LETTERS
- Intracellular Leptin-Signaling Pathways in Hypothalamic Neurons: The Emerging Role of Phosphatidylinositol-3 Kinase-Phosphodiesterase-3B-cAMP Pathway
- (2011) Abhiram Sahu NEUROENDOCRINOLOGY
- Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85 Src homology-2 domains
- (2011) J. Y. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry
- (2010) Roberto Caporali et al. AUTOIMMUNITY REVIEWS
- Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
- (2010) Richard J. Riese et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Activation of the interferon-γ signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells
- (2009) Thomas Karonitsch et al. ARTHRITIS AND RHEUMATISM
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor α Homodimers
- (2009) Tekla Hornakova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CD20-depleting therapy in autoimmune diseases: from basic research to the clinic
- (2009) F. Perosa et al. JOURNAL OF INTERNAL MEDICINE
- Leptin and Coronary Heart Disease
- (2009) Naveed Sattar et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- JAK mutations in high-risk childhood acute lymphoblastic leukemia
- (2009) C. G. Mullighan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activating mutations in human acute megakaryoblastic leukemia
- (2008) S. Malinge et al. BLOOD
- Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome
- (2008) Tomohiko Sato et al. BRITISH JOURNAL OF HAEMATOLOGY
- Somatically acquiredJAK1mutations in adult acute lymphoblastic leukemia
- (2008) Elisabetta Flex et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias
- (2008) Wanlong Ma et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- SOCS regulation of the JAK/STAT signalling pathway
- (2008) Ben A. Croker et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Identification of somatic JAK1 mutations in patients with acute myeloid leukemia
- (2007) Z. Xiang et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started